Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2023 | FORMULA-509 rationale + trial design: the addition of AAP + apa post-radical prostatectomy

Paul L. Nguyen, MD, Dana-Farber Cancer Institute, Boston, MA, shares the rational and trial design of the Phase II randomized FORMULA-509 (NCT03141671) trial assessing post-operative salvage radiotherapy and 6 months of GnRH agonist with or without abiraterone acetate/prednisone and apalutamide post-radical prostatectomy in patients with a rising PSA after radical prostatectomy. The standard treatment for patients with prostate cancer is usually salvage radiation with 6 months of androgen deprivation therapy (ADT). The trial assessed whether adding 6 months of apalutamide and abiraterone could improve outcomes compared to the standard of 6 months of bicalutamide with 6 months of ADT. Patients had PSA≥0.1 post-radical prostatectomy and one or more unfavorable features (Gleason 8-10, PSA more than 0.5 pT3/T4, pN1 or radiographic N1, PSA doubling time less than 10 months, negative margins, persistent PSA, gross local/regional disease, or Decipher High Risk) and were stratified by PSA level and node positivity. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.